Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBET: Trifluridine/tipiracil in ER-positive, HER2-negative advanced breast cancer
2024-519204-27-00Phase 2Completed
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free at 8 weeks. Started Nov 2024; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519204-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519204-27-00.